CureMetrix and Therapixel Collaborate to Expand Access to Breast AI Imaging Solutions

CureMetrix and Therapixel have announced a new partnership designed to expand access to advanced breast imaging AI tools by integrating CureMetrix’s cmAngio® with Therapixel’s MammoScreen®. The collaboration aims to streamline clinical workflows and enhance the value of routine mammography for women and healthcare providers.

cmAngio is the first—and currently only—FDA-cleared AI software that identifies and localizes Breast Arterial Calcifications (BAC) on screening mammograms. By marking these findings for radiologists, the technology helps flag women who may benefit from further cardiovascular evaluation. 

MammoScreen, Therapixel’s flagship AI, assists radiologists in detecting breast cancer by analyzing 2D and 3D mammograms along with prior exams. The tool generates an intuitive score to guide interpretation and includes features such as image-quality checks, patient-history alerts, and draft reporting to reduce reading time. Clinical studies show the system can lessen fatigue and reduce variability between readers, supporting more consistent care. Together, the integrated tools offer what the companies describe as a more holistic approach to women’s health. By screening for both breast cancer and arterial calcifications in a single exam, the combined solution effectively turns mammography into “a 2-for-1” assessment.

“This partnership aligns two innovators committed to transforming women’s health,” said Kevin Harris, President of CureMetrix. “cmAngio is live at hundreds of sites across the US and has been offered to almost 1 million women. By integrating cmAngio with Therapixel’s MammoScreen, we are broadening our reach, unifying installation for customers, and helping radiologists deliver deeper, data-driven insights that can improve outcomes for patients.”

Therapixel CEO Matthieu Leclerc-Chalvet emphasized the added clinical value the partnership brings to imaging practices. “We’re proud to partner with CureMetrix to bring even more clinical value to our customers,” he said. “Two best-in-class products, MammoScreen and cmAngio, now combine to empower radiologists to work smarter, improve quality and consistency, and make more informed decisions in breast imaging. Improving women’s health and patient outcomes is our mission, and by detecting breast arterial calcifications that often go unnoticed or unreported, we are advancing that mission.”

The integration is expected to simplify implementation for healthcare sites while expanding access to AI tools that support earlier detection and more comprehensive patient evaluation.